Zacks Research Increases Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX) – Investment analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of Surmodics in a research note issued on Monday, November 25th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.14 per share for the year, up from their prior forecast of $0.13. The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.81 EPS.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.14. The firm had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%.

Several other research analysts also recently weighed in on the company. StockNews.com initiated coverage on Surmodics in a research note on Saturday, November 23rd. They set a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Thursday, November 7th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Down 0.1 %

Shares of NASDAQ:SRDX opened at $39.54 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22. The company has a market capitalization of $566.61 million, a PE ratio of -48.65 and a beta of 1.20. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The business has a fifty day moving average price of $38.50 and a two-hundred day moving average price of $39.58.

Insider Transactions at Surmodics

In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the transaction, the chief financial officer now owns 70,350 shares in the company, valued at $2,774,604. This trade represents a 9.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRDX. Gabelli Funds LLC boosted its stake in Surmodics by 393.7% in the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company’s stock worth $10,939,000 after purchasing an additional 207,500 shares during the period. Gardner Lewis Asset Management L P bought a new position in Surmodics in the 2nd quarter worth about $8,531,000. Phocas Financial Corp. purchased a new stake in shares of Surmodics in the 3rd quarter valued at about $3,430,000. Nisa Investment Advisors LLC raised its holdings in shares of Surmodics by 4,722.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company’s stock valued at $2,877,000 after acquiring an additional 67,010 shares in the last quarter. Finally, Versor Investments LP purchased a new stake in shares of Surmodics in the 2nd quarter valued at about $2,723,000. Institutional investors own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).